Cargando…
A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs
We have generated fusion proteins between vascular endothelial growth factor (VEGF) and the bacterial enzyme carboxypeptidase G2 (CPG2) that can activate the prodrug 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA). Three asparagine residues of CPG2 were mutated to glutamine (...
Autores principales: | Spooner, R A, Friedlos, F, Maycroft, K, Stribbling, S M, Roussel, J, Brueggen, J, Stolz, B, O'Reilly, T, Wood, J, Matter, A, Marais, R, Springer, C J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377106/ https://www.ncbi.nlm.nih.gov/pubmed/12771932 http://dx.doi.org/10.1038/sj.bjc.6600911 |
Ejemplares similares
-
Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol
por: Tupper, J, et al.
Publicado: (2004) -
Anti-tumour activity and toxicity of the new prodrug9-aminocamptothecin glucuronide (9ACG) in mice
por: Prijovich, Z M, et al.
Publicado: (2002) -
Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo
por: Theys, J, et al.
Publicado: (2006) -
Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity
por: Rephaeli, A, et al.
Publicado: (2007) -
Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
por: Deckert, P M, et al.
Publicado: (2003)